Join to View Full Profile
850 Southampton AveNorfolk, VA 23510
Phone+1 757-668-9920
Fax+1 757-668-9930
Are you Dr. Proud?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Crystal Proud, MD is a Child Neurologist in Norfolk, Virginia. She is currently licensed to practice medicine in Virginia, North Carolina, and California.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Child Neurology, 2011 - 2014
Emory University School of MedicineResidency, Pediatrics, 2009 - 2011
Eastern Virginia Medical SchoolClass of 2009
Certifications & Licensure
CA State Medical License Current
VA State Medical License 2015 - 2026
NC State Medical License 2022 - 2025
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology- American Board of Psychiatry and Neurology Neuromuscular Medicine
Publications & Presentations
PubMed
- 1 citationsSpinal Muscular Atrophy Update in Best Practices: Recommendations for Treatment Considerations.Mary K Schroth, Jennifer Deans, Diana X Bharucha Goebel, W Bryan Burnette, Basil T Darras
Neurology. Clinical Practice. 2025-02-01 - 12 citationsAAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.Jerry R Mendell, Francesco Muntoni, Craig M McDonald, Eugenio M Mercuri, Emma Ciafaloni
Nature Medicine. 2025-01-01 - Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy: A Call for Discussion.Omer Abdul Hamid, D Micah Hester, Susan E Matesanz, Sarah Wright, Kaitlin Y Batley
Pediatric Neurology. 2024-10-01
Press Mentions
New Novartis Phase III Data Demonstrate Meaningful Efficacy and Safety Results of Intrathecal Onasemnogene Abeparvovec in Broad Patient Population with SMAMarch 19th, 2025
Gene Therapy from Novartis Shows Promise for Children with SMAJanuary 2nd, 2025- Novartis Intrathecal Onasemnogene Abeparvovec Phase III Study Meets Primary Endpoint in Children, Young Adults with Spinal Muscular AtrophyDecember 30th, 2024
